Archive: Company News

Company News: Probiodrug Obtains Patent, Expands Boards, Wins Award

Alzheimer-specialist Probiodrug AG last week not only obtained a new US patent covering the inhibition of the enzyme glutaminyl cyclase (QC) for the treatment of CNS diseases. The company also announced the appointment of Dr Claus Braestrup, former President & CEO of Lundbeck A/S to Chairman of the Supervisory Board and Prof Dr Lennart Mucke, Director of the Gladstone Institute of Neurological Disease in San Francisco, Calif. to its Scientific Advisory Board.  Moreover, the company was awarded the “IQ Innovationspreis Mitteldeutschland” by the Industrial Initiative for Central Germany for its innovative therapeutic strategy to combat Alzheimer’s disease. In May, Probiodrug hosted the PSP 2010 conference with more than 150 scientists to discuss its approach.

Company News: Micromet Presents Updated Results From Phase 1 and Phase 2 Study of Blinatumomab

– Update Presented at the 15th Annual Congress of the European Hematology Association (EHA) –

Micromet, Inc. (NASDAQ: MITI) today announced updated clinical data from a Phase 1 and a Phase 2 trial, respectively, of its lead product blinatumomab (MT103). The data were presented at the 15th Annual Congress of the European Hematology Association (EHA) in Barcelona, Spain.

Results of the analysis from a Phase 2 trial in adult patients with minimal residual disease (MRD) positive acute lymphoblastic leukemia (ALL) demonstrate that a prolonged hematologic relapse-free survival was observed in patients treated with blinatumomab. A pivotal trial in adult MRD-positive ALL patients is scheduled to begin in Q3, 2010.

Updated results from a Phase 1 trial of blinatumomab in patients with relapsed non-Hodgkin’s lymphoma (NHL) demonstrated durable responses ranging up to 30 months. Blinatumomab is the first in a new class of agents called BiTE® antibodies, designed to harness the body’s T cells to kill cancer cells.

A conference call will be hosted tomorrow, June 15, 2010, at 08:30am ET / 02:30pm CET / 01:30pm UK time. Dial-in details and the complete announcements are available here.

Company News: 365 Energy Selected as Provider of ChargePoint® Networked Charging Stations in Poland

365 Energy and partner Zohar Energy start collaboration with POLENERGIA

365 Energy today announced that its partner Zohar Energy has been chosen by Polish energy company POLENERGIA to support its expansion as a leading provider of infrastructure solutions for electric vehicles (EVs) in Poland. The first ChargePoint® Networked Charging Station was installed in Warsaw earlier this month. The ChargePoint stations are manufactured by US-based Coulomb Technologies. More information is available here.

Company News: MediGene Expands Commercialization of Veregen to China and South Korea

– Closing of two additional license and supply agreements for the commercialization and marketing of Veregen® –

MediGene AG (Frankfurt, Prime Standard, TecDAX) has signed two further license and supply agreements for the commercialization and marketing of Veregen®. These have been signed with GC-Rise Pharmaceutical Co., Ltd. in China and JS Bio Pharm Co., Ltd. in South Korea.

GC-Rise will conduct the clinical trials of Veregen® (for the treatment of genital warts) that are required for approval of the ointment in China, and will be responsible for all the regulatory and approval procedures thereafter. MediGene will receive a one-time payment upon execution of the agreement and a further milestone payment upon initiation of the first clinical trial in China. In addition, MediGene will profit from supplying GC-Rise with the drug product. GC-Rise expects market launch in China at the end of 2013.

JS Bio Pharm will promote and distribute Veregen® for the treatment of genital warts, and will also be responsible for all regulatory procedures and for obtaining approval of the drug in South Korea. MediGene will receive royalties and a milestone payment contingent on the level of sales achieved. In addition, MediGene will profit from supplying JS Bio Pharm with the drug product. JS Bio Pharm expects to launch the drug on the South Korean market during 2012.

Please click here for more information.

1 119 120 121 124